AgomAb Therapeutics (AGMB) Stock Price, News & Analysis

Company Overview

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company's name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones. The company emphasizes creating antibody formats that mimic or enhance natural ligand-receptor interactions to restore or improve biological signaling. While specific programs and indications evolve with research and regulatory progress, AgomAb’s platform is positioned to address therapeutic areas that may benefit from receptor activation rather than inhibition.

AgomAb conducts its research and development through in-house scientific teams and may pursue strategic partnerships or collaborations to advance lead candidates toward clinical testing and commercialization. Public disclosures such as SEC filings, company press releases and investor presentations are the primary sources for up-to-date information on the company’s pipeline, program timelines, corporate leadership and geographic footprint. Investors and analysts should consult those documents for specific details about AgomAb’s ongoing programs and corporate developments.

Key Stats

• Today's Range: $11.55 to $12.69
• 50-Day Range: $9.85 to $16.21
• 52-Week Range: $9.00 to $17.45
• Volume: 100,647 shs
• Average Volume: 171,608 shs
• Market Capitalization: $452.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Moderate Buy

AGMB Stock Analysis - Frequently Asked Questions

How have AGMB shares performed this year?

AgomAb Therapeutics' stock was trading at $15.15 at the beginning of the year. Since then, AGMB stock has decreased by 17.5% and is now trading at $12.50.

When did AgomAb Therapeutics IPO?

AgomAb Therapeutics (AGMB) raised $200 million in an initial public offering (IPO) on Friday, February 6th 2026. The company issued 12,500,000 shares at $15.00-$17.00 per share.

When did AgomAb Therapeutics' quiet period expire?

AgomAb Therapeutics's quiet period expired on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its IPO on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. During AgomAb Therapeutics' quiet period, insiders and underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of AgomAb Therapeutics?

Shares of AGMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGMB
• CIK: 2020932
• Web: N/A
• Phone: (323) 302-3530
• Fax: N/A
• Employees: 62
• Year Founded: 2017

Price Target and Rating

• Average Price Target for AgomAb Therapeutics: $32.00
• High Price Target: $36.00
• Low Price Target: $28.00
• Potential Upside/Downside: +156.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 36,237,000
• Free Float: N/A
• Market Cap: $452.96 million
• Optionable: N/A
• Beta: N/A